Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes

Key points
- This study uses functional magnetic resonance imaging (fMRI) to learn how the brain functions in adolescents receiving fluoxetine (Prozac) cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) for anxiety or depression in children/adolescents.
- All participants will receive interviews to assess how they are doing in general, including general mood, degree of nervousness and behavior.
- Participants with anxiety or depression will first meet with a psychiatrist or psychologist for two weekly sessions of talk therapy.
- Those who have not improved by the end of the study will be offered other treatment for 1 to 3 months, and the clinicians will help with finding subsequent aftercare.
This study uses functional magnetic resonance imaging (fMRI) to learn how the brain functions in adolescents receiving fluoxetine (Prozac) cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) for anxiety or depression in children/adolescents.
All participants will receive interviews to assess how they are doing in general, including general mood, degree of nervousness and behavior. Each participant and one of his or her parents will be interviewed separately and together. Those electing the medication study will also receive a physical examination. Participants are asked to complete tasks involving problem-solving and memory that involve looking at pictures, remembering things, testing reaction times, and making simple choices.
Participants with anxiety or depression will first meet with a psychiatrist or psychologist for two weekly sessions of talk therapy. Those who remain anxious or depressed after these 2 weeks will have the 3 options based on their choice: 1) treatment with fluoxetine daily for 8 weeks 2) cognitive-behavioral therapy or interpersonal therapy (two kinds of talk therapy) once a week for 8 weeks 3) a random assignment (50% chance) to either placebo or fluoxetine for 8 weeks. During and after the 8 weeks of treatment, each participant will complete verbal and written symptom ratings. Blood samples will be drawn for laboratory tests before drug treatment and after it ends.
Those who have not improved by the end of the study will be offered other treatment for 1 to 3 months, and the clinicians will help with finding subsequent aftercare. Those who improve with treatment will continue therapy at NIH until an outside physician is able to assume responsibility for monitoring medication.
FOR MORE INFORMATION REGARDING THIS STUDY CALL THE CORE PHONE NUMBER: 301-496-5645
Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00018057
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Mental Health →
NewsIncense may calm anxiety, depression
If the scent of burning incense helps you relax, a new animal study may help explain why. In mice, scientists found, a component of frankincense appears to activate particular brain pathways to calm anxiety- and…
12 June 2008
NewsResearch: Coping with Anxiety, Depression, Schizophrenia
Research is shedding new light on what happens in the brains of children and adults affected by clinical depression, anxiety disorders and schizophrenia, according to Washington University in St. Louis studies presented…
1 June 2008
NewsInsomnia Patients with Anxiety, Depression Often Denied Sleep Meds
Patients with insomnia who are diagnosed with accompanying mental health ailments often are not prescribed medication that will help them sleep – which could then make related anxiety or depression worse, new research…




